Pfizer, BioNTech launch US trial for novel COVID-19 vaccineUS drug maker Pfizer Inc. and Germany biopharmaceutical company BioNTech announced today that the first US participants in a clinical trial for a novel coronavirus vaccine have begun receiving doses.The phase 1 and 2 trial for the BNT162 vaccine program is designed to determine the safety, immunogenicity, and optimal dose levels of four mRNA vaccine candidates simultaneously.
The first US subjects enrolled in the first stage of the study, which will enroll up 360 healthy participants, are healthy adults 18 to 55 years of age.
Once testing in this group has provided initial evidence of safety and immunogenicity, an older cohort of subjects (65 to 85 years old) will receive doses.US